

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : C07D 475/00, 487/00, 239/02 C07D 405/04, 473/00</p>	<p>A1</p>	<p>(11) International Publication Number: WO 92/10496 (43) International Publication Date: 25 June 1992 (25.06.92)</p>
<p>(21) International Application Number: PCT/US91/09123 (22) International Filing Date: 5 December 1991 (05.12.91) (30) Priority data: 622,762 5 December 1990 (05.12.90) US 699,197 13 May 1991 (13.05.91) US (71) Applicant: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US/US); Boyd Graduate Stud- ies Research Center, Athens, GA 30602 (US). (72) Inventors: CHU, Chung, K. ; 120 Orchard Knob Lane, Athens, GA 30605 (US). BEACH, J., Warren ; 660 East Campus Road, #65, Athens, GA 30605 (US). JEONG, Lak-Shin ; 300 Rogers Road, #R312, Athens, GA 30605 (US).</p>	<p>(74) Agents: PRATT, John, S. et al.; Kilpatrick & Cody, 100 Peachtree Street, Suite 3100, Atlanta, GA 30303 (US). (81) Designated States: AT (European patent), AU, BE (Euro- pean patent), CA, CH (European patent), DE (Euro- pean patent), DK (European patent), ES (European pa- tent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (Euro- pean patent), MC (European patent), NL (European pa- tent), SE (European patent). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(54) Title: ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES</p> <p>(57) Abstract</p> <p>An asymmetric process for the preparation of enantiomerically pure β-L-(-)-1,3-oxathiolane-nucleosides that includes the initial preparation of the key chiral intermediates (2R,5R) and (2R,5S)-5-(O-protected)-2-(protected-oxymethyl)-1,3-oxathiolane from 1,6-thioanhydro-L-gulose. The 2R,5(R,S)-5-(O-protected)-2-(protected-oxymethyl)-1,3-oxathiolane is condensed with a desired heterocyclic base, typically a purine or pyrimidine base, to provide the product nucleoside. The synthesis can be used to prepare the pharmaceutically important compound, β-L-(-)-1-[(2R,4R)-2-(hydroxymethyl)-4-(1,3-thioxolane)]cytosine (β-L-(-)-BCH-189).</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU ⁺	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE*	Germany	MC	Monaco	US	United States of America
DK	Denmark				

⁺ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

-1-

ENANTIOMERICALLY PURE β -L-1,3-OXATHIOLANE NUCLEOSIDES

The government has rights in this invention by virtue of grants from the Public Health Service of the National Institute of Allergy and Infectious Diseases.

Background of the Invention

This invention is in the area of the organic synthesis of nucleosides, and in particular relates to a process for the preparation of enantiomerically pure β -L-1,3-oxathiolane nucleosides.

A nucleoside is a molecule consisting of a 5-carbon sugar and a purine or pyrimidine base. Addition of a phosphate group to the 5'-position of the nucleoside converts the nucleoside into a nucleotide. Natural nucleotides are the building blocks for the nucleic acids, RNA (ribonucleic acid) and DNA (deoxyribonucleic acid).

In 1985, it was reported that the synthetic nucleoside 3'-azido-3'-deoxythymidine (AZT) inhibits the replication of human immunodeficiency virus type 1 (referred to below as HIV). Mitsuya, H., et al., Proc. Natl. Acad. Sci. U.S.A. 82, 7096 (1985). HIV is believed to be the etiological cause of acquired immunodeficiency syndrome (AIDS). Since then, a number of other synthetic nucleosides having anti-HIV activity have been identified, including 3'-azido-2',3'-dideoxyuridine (referred to as AZDU, or CS-87), 3'-azido-2',3'-dideoxycytidine (CS-91), 3'-azido-5-methyl-2',3'-dideoxycytidine (CS-92), 5-ethyl-3'-azido-2',3'-dideoxyuridine (CS-85), and 3'-fluoro-3'-deoxythymidine (FDT). In the 5'-triphosphorylated form, these nucleosides are known to inhibit HIV reverse transcriptase as well as cause chain-termination of the growing viral DNA chain.

AZT has been approved by the U.S. Food and Drug Administration for administration to patients with AIDS and AIDS-related complex. Several of the other synthetic nucleoside derivatives are undergoing various stages of clinical trials, including 2',3'-dideoxyuridine, 2'.3'-dideoxyinosine, 2',3'-dideoxycytidine, 3'-deoxy-2',3'-didehydrothymidine, and 2'-fluoro-arabinofuranosyl-2'-3'-dideoxycytidine.

The stereochemistry of nucleoside derivatives play an important role in their biological activity. The C1' position of the ribose in the nucleoside (the carbon bound to the nitrogen of the heterocyclic base, see Figure 1) is a chiral center because the carbon is attached to four different moieties. Likewise, there is an optically active center at C4' of the nucleoside (the ring carbon bound to the hydroxymethyl group that is phosphorylated in nucleotides). In the naturally occurring nucleosides, both the base attached to the C1' atom and the hydroxymethyl group attached to the C4' atom are on the same side of the carbohydrate ring.

A carbohydrate configuration in which the C1' and C4'-substituents are on the same side of the carbohydrate plane (i.e., the substituents are cis) is referred to as a " β -configuration." A carbohydrate configuration in which the C1' and C4'-substituents are on the opposite side of the carbohydrate plane (i.e., the substituents are trans) is referred to as an " α -configuration". Referring to compound 1 of Figure 2, a nucleoside is designated a D-nucleoside if the non-hydrogen substituent attached to the C4'-atom is above the plane of the carbohydrate ring. The nucleoside is designated an L-nucleoside if the non-hydrogen substituent attached to the C4'-atom is below the plane of the carbohydrate ring.

The non-naturally occurring α -isomers of nucleosides (in which the C1' or C4' substituents are on opposite sides of the carbohydrate plane) are rarely biologically active, and are typically toxic.

5 An analysis of the solid-state conformations of six active and two inactive anti-HIV nucleoside agents was recently performed to attempt to correlate the presence or absence of certain stereochemical features with high anti-HIV activity. Van Roey, P., et al., J. Am. Chem. Soc., 1988, 110, 2277; and Van Roey, P., et
10 al., Proc. Natl. Acad. Sci. U.S.A., 1989, 86, 3929. The x-ray structures indicated that active anti-HIV nucleosides assume the C3'-exo or similar carbohydrate conformations while inactive compounds prefer the C3'-
15 endo conformation. (Endo and exo refer to the conformations in which the atoms are at the same or opposite side of the sugar ring in relation to the base). The C3'-exo and C3'-endo conformations place the C5' atom in axial and equatorial positions,
20 respectively. The position of the C5' atom affects the location of the 5'-hydroxyl group in relation to the base. Since the 5'-hydroxyl group is the site of phosphorylation of the nucleoside, its location with respect to the rest of the nucleoside is important.

25 Recently, several unusual types of nucleosides have been shown to be potent antiviral agents, including (\pm)-1-(1,3-oxothiolany)-cytosine (also referred to as (\pm) BCH-189), (-)-1-[(2B,4B)-2-(hydroxymethyl)-4-dioxolanyl]thymine (also referred to
30 as dioxolane-T), oxetanocin, 6-phenylthio-uracil-acyclonucleosides, and cyclobutane carbocyclic nucleosides. BCH-189 (a 1,3-oxathiolane nucleoside) and dioxolane-T are particularly interesting in that the 3'-CH₂ groups of the ribose moieties of these

nucleosides are replaced by sulfur and oxygen atoms, respectively, as shown in Figure 1.

Norbeck, D.W., et al., in Tet. Lett., 1989, 30, 6263, reported a synthesis of (\pm)-dioxolane-T, that
5 results in a racemic mixture of enantiomers about the C4' atom. The product was synthesized in five steps from benzyloxyaldehyde dimethylacetal and (\pm)-methyl glycerate to produce a 79% yield of a 1:1 diastereomeric mixture. The X-ray crystallographic
10 analysis of the product revealed that the dioxolane ring adopts the 3T_4 conformation commonly observed in ribonucleosides, with the O3' atom in the endo position. Norbeck reported that the racemic mixture of dioxolane-T exhibits an anti-HIV activity of 20 μ M
15 in ATH8 cells, and attributed the low efficacy against the virus to an effect of the endo conformation of the O3' atom.

U.S.S.N. 07/622,762 entitled "Enantiomerically Pure β -D-(-)-Dioxolane-Nucleosides," filed on December
20 5, 1990, by Chung K. Chu and Raymond F. Schinazi, discloses a synthesis of enantiomerically pure β -(-)-dioxolane-nucleosides (dioxolane nucleosides in which both the substituents in the C1' and the C4' position are in the β -position) from D-mannose via 1,6-anhydro-D-mannose. The anti-HIV activity enantiomerically
25 pure β -D-(-)-dioxolane-T in peripheral blood mononuclear cells was measured at 0.3 μ M, indicating that the naturally occurring enantiomerically pure β -nucleoside is substantially more active than the prior
30 known racemic mixture that included the nonnaturally-occurring isomer. The enantiomerically pure nucleoside is also less toxic than the racemic mixture, presumably because of the absence of the nonnaturally occurring derivative.

Belleau, et al., in the Fifth International Conf. on AIDS, Montreal, Canada June 4-9, 1990, paper No. T.C.O.1., reported a method of synthesis of cytidine nucleosides that contain oxygen or sulfur in the 3'-position. The dioxolane ring was prepared by the condensation of $\text{RCO}_2\text{CH}_2\text{CHO}$ with glycerine. As with the Norbeck synthesis, the Belleau synthesis results in a racemic mixture about the C4'-carbon of the nucleoside. (\pm) BCH-189 (referred to by Belleau as NGBP-21) has been shown to have a potent anti-HIV activity (EC_{50} = 0.03, 0.2 and 0.05 μM in CEM, MT4, and PBM cells, respectively) with an excellent bone marrow toxicity profile. (\pm)-BCH-189 is currently undergoing preclinical toxicology.

U.S.S.N. 07/699,197, filed on May 13, 1991, described a synthesis of $\beta\text{-D-(+)-1-}[(2\text{B},4\text{B})\text{-2-(hydroxymethyl)-4-(1,3-oxathiolane)}]\text{cytosine}$ from 1,6-thioanhydro-D-mannose. Since the $\beta\text{-D}$ isomers of nucleosides are in general the biologically active isomers, it was expected that this form of BCH-189 would exhibit the highest activity of the BCH-189 enantiomers. Surprisingly, it was found that the $\beta\text{-D-(+)}$ isomer 2 (EC_{50} = 0.32 μM) was significantly less potent than the racemic (\pm) BCH-189 1 (EC_{50} = 0.06 μM) in human peripheral blood mononuclear (PBM) cells. Furthermore, the $\beta\text{-D-(+)}$ isomer 2 was found to be inactive against HBV (Hepatitis B Virus), while the racemic mixture was found to have HBV activity. In light of this information, it was desired to synthesize the $\beta\text{-L-(-)}$ 3 and the $\alpha\text{-L-(+)}$ 5 isomers and compare their anti-HIV and anti-HBV activities to those of (\pm) BCH-189.

There is also a need for a synthesis of $\beta\text{-L-(-)-1,3-oxathiolane}$ nucleosides in general as a research tool to provide more information on the effect of

stereochemistry on the anti-viral activity of nucleoside derivatives, and to provide new anti-HIV agents.

It is therefore an object of the present invention to provide a method of synthesis of enantiomerically pure β -L-1,3-oxathiolane nucleosides.

Summary of the Invention

10 An asymmetric process for the preparation of enantiomerically pure β -L-(-)-1,3-oxathiolane-nucleosides is presented. The process involves the initial preparation of the key chiral intermediate 2R,5(R,S)-5-(O-protected)-2-(protected-oxymethyl)-
15 1,3-oxathiolane from 1,6-thioanhydro-L-gulose, a sugar that has the required stereochemistry for the production of the β -L-(-)-1,3-oxathiolane nucleoside, including the correct diastereomeric configuration about the 2 position of the sugar (that becomes the
20 4'-position in the later formed nucleoside). 1,6-Thioanhydro-L-gulose is easily prepared from L-gulose.

The 2R,5(R,S)-5-(O-protected)-2-(protected-oxymethyl)-1,3-oxathiolane is condensed with a desired heterocyclic base in the presence of SnCl_4 , other
25 Lewis acid, or trimethylsilyl triflate in an organic solvent such as dichloroethane, acetonitrile, or methylene chloride, to provide the stereochemically pure β -L-(-)-1,3-oxathiolane-nucleoside.

Products made according to this process can be
30 used as a research tool to study the inhibition of HIV in vitro or can be administered in a pharmaceutical composition to inhibit the growth of HIV in vivo.

The process described herein can be used to prepare the pharmaceutically important compound, β -L-

(-)-1-[(2S,4S)-2-(hydroxymethyl)-4-(1,3-oxathiolane)]cytosine (8-L-(-)BCH-189).

As an example (see Figures 3 and 4), synthesis of 1,6-thioanhydro-L-gulose 9 was accomplished in 4 steps from L-gulose 6. Selective 6-O-tosylation followed by acetylation gave 1,2,3,4-tetra-O-acetyl-6-O-tosyl-L-gulose 7 as a foam in 96.7% yield. Treatment of 7 with 3 molar equivalents of HBr/AcOH (45% w/v) using acetic acid as solvent gave the bromo sugar 8 (99%). Reaction of the bromo sugar 8 with 3.3 molar equivalent of potassium O-ethylxanthate in refluxing acetone gave 2,3,4-tri-O-acetyl-1,6-thioanhydro-L-gulose, which was not isolated, but was deacetylated using NH₄OH/MeOH to give 1,6-thioanhydro-L-gulose 9 (72% from 8) as a crystalline solid. Treatment of 9 with NaIO₄ at -10°C was carried out to cleave the 2,3-cis diol, and then the resulting aldehyde (2-formyl-5-(2'-(2'-hydroxyacetaldehyde)-1,3-oxathiolane) was reduced with NaBH₄. The vicinal diol (2-hydroxymethyl-5-(2'-(1',2'-dihydroxyethyl)-1,3-oxathiolane) was protected as the isopropylidene derivative 10 (60%). Silylation of the remaining primary alcohol followed by treatment with 10% HCl in MeOH at -10°C gave protected diol 11. Oxidative cleavage of the resulting diol 11 with Pb(OAc)₄ followed by further oxidation with pyridinium dichromate (PDC) in DMF gave the acid 12 without oxidation of the ring sulfide group to the sulfoxide. Oxidative decarboxylation of 12 using Pb(OAc)₄/pyridine in dry THF gave the acetate 13 (66% from 11). Condensation of 13 with silylated N-acetylcytosine in dry 1,2-dichloroethane using trimethylsilyl triflate as the Lewis acid catalyst gave an α,β-mixture 1:2) of 14 and 15 (64%). Separation of the anomers by silica gel chromatography

followed by deacetylation using NH_3/MeOH and desilylation using tetra-*n*-butylammonium fluoride gave the final compounds, $\beta\text{-L-}(-)$ isomer 3 and $\alpha\text{-L-}(+)$ isomer 5, respectively.

5

Brief Description of the Figures

Figure 1 is an illustration of a 1,3-oxathiolane nucleoside with the C1' and C4' chiral carbon atoms indicated by asterisk.

10

Figure 2 is an illustration of the $\beta\text{-D-}(+)$ and $\beta\text{-L-}(-)$ isomers of 1-[(2 β ,4 β)-2-(hydroxymethyl)-4-(1,3-oxathiolane)]cytosine (BCH-189).

Figure 3 is an illustration of the process for the preparation of 1,6-dideoxy-1,6-thioanhydro-L-gulose.

15

Figure 4 is an illustration of the process for the preparation of $\beta\text{-L-}(-)$ -1-[(2 β ,4 β)-2-(hydroxymethyl)-4-(1,3-oxathiolane)]cytosine.

20

Detailed Description of the Invention

As used herein, the term "protected" refers to a moiety that has been placed on a functional group of a molecule to prevent further reaction of the moiety during derivatization of another portion of the molecule. Protecting groups, particularly for oxygen and nitrogen, are well known to those skilled in the art of organic chemistry.

25

The term "1,3-oxathiolane nucleoside" as used herein refers to a nucleoside derivative as depicted in Figures 1 and 2, wherein a 1,3-oxathiolane is attached to a heterocyclic base, typically a purine or pyrimidine base, through the oxathiolane C5 carbon (that becomes the C1'-carbon in the nucleoside).

30

The process for the preparation of enantiomerically pure β -L-(-)-1,3-oxathiolane nucleosides proceeds in two stages. In the first stage, a 1,3-oxathiolane derivative is prepared that includes a hydroxymethyl group in the chiral 2-position (that will become the hydroxymethyl group in the C4' position of the nucleoside) with the proper stereochemistry for the final enantiomerically pure β -L-(-)-nucleoside. In the second stage, the 1,3-oxathiolane is condensed with a heterocyclic base at the C5 position to produce a 1,3-oxathiolane nucleoside that has both the C1' (heterocyclic base) and the C4' (hydroxymethyl) substituents in the desired position.

The compounds referred to below are numbered as illustrated in Figures 2, 3, and 4.

A. Preparation of 1,3-Oxathiolane Derivative

20 Preparation of 1,6-Thioanhydro-L-gulose

The starting material for this process for the preparation of enantiomerically pure β -L-(-)-1,3-oxathiolane nucleosides is 1,6-thioanhydro-L-gulose (Figure 3, compound 2), that has the appropriate chiral center at C2 for the preparation of the desired β -L-(-)-(1,3)-oxathiolane nucleosides.

1,6-Thioanhydro-L-gulose can be prepared from L-gulose (Figure 3, compound 5) in 3 steps (Figure 3). L-Gulose can be prepared from L-gulonolactone, that in turn can be prepared from D-glucurono-6,3-lactone that is readily available and inexpensive. Lerner, L.M., et al., J. Org. Chem. 33, 1780 (1968); Evans, M. E., et al., Carbohydrate Research 28, 359 (1973); and Ishidate, M., et al., Chem. Pharm. Bull. 13, 173 (1965).

In the first step, the hydroxyl groups in gulose are protected. Taking advantage of the principle that reactivity in tosylation, and in esterification generally, decreases in the order primary alcohol > secondary alcohol > tertiary alcohol, the primary hydroxyl group at C₆ is initially selectively tosylated. The temperature used for this initial protecting step should be the lowest that allows for C₆ esterification without reaction of the other four hydroxyl groups in the molecule, preferably between 18 and 20 degrees C. Tosylation can be performed with p-toluenesulfonyl chloride and pyridine, or under other conditions known to those in the art. After the C₆-hydroxyl group is protected, the other four hydroxyl groups are protected, preferably with an acetyl moiety, to provide 1,2,3,4-tetra-O-(protected)-6-O-(protected)-L-gulopyranoside 2. Other suitable oxygen protecting groups are known to those skilled in the art, and include benzoate. This reaction should be performed at the lowest temperature under which reaction occurs, preferably between 18 and 20 degrees C.

In the second step according to this procedure, the 1-position of 1,2,3,4-tetra-O-(protected)-L-gulopyranoside 2 is converted to 2,3,4-tri-O-(protected)-1-halo-6-O-(protected)- α -L-gulopyranoside 3 by reaction with HX, wherein X is bromo or chloro. In a preferred embodiment, the reaction is performed in acetic acid at a temperature range of between 0 and 25 degrees C, for a time period of between six and eight hours.

In the third step, the gulopyranoside 3 is easily converted to 2,3,4-tri-O-(protected)-1,6-dideoxy-1,6-thioanhydro-L-gulose by reaction with potassium O-ethyl xanthate, which can be purchased commercially

from Aldrich Chemical Company, or prepared from KOH and carbon disulfide in ethanol. Alternatively, NaSH or (Na)₂S can be used. The reaction is easily carried out in refluxing acetone. Typically, between 3.0 and 5 3.5 equivalents of xanthate reagent are used.

In the fourth step, 2,3,4-tri-O-(protected)-1,6-dideoxy-1,6-thioanhydro-L-gulose is then deprotected under basic conditions at ambient temperature to provide 1,6-thioanhydro-L-gulose 2. Any base is 10 suitable in this deprotection step, including ammonium hydroxide, sodium hydroxide, potassium hydroxide, and sodium methoxide. It is preferred that the pH be maintained at less than 9.

In preparing these enantiomerically pure 8-L-1,3-oxathiolane nucleosides, care should be taken to avoid 15 strong acidic conditions that would cleave the 1,3-oxathiolane ring. Reactions should be performed, if possible, in basic or neutral conditions, and when acidic conditions are necessary, the time of reaction 20 should be minimized.

Conversion of 1,6-Thioanhydro-L-Gulose to 1,3-Oxathiolane Derivatives

25 According to this process, 1,6-thioanhydro-L-gulose 2 is easily converted to a 1,3-oxathiolane derivative via direct cleavage of the unprotected thioanhydro-L-gulose followed by reduction to the corresponding diol, isopropylidenation of the diol, 30 silylation of the 2-hydroxymethyl group, and deisopropylidenation (see Figure 4), or by initial isopropylidenation of 1,6-thioanhydro-L-gulose, protection of the remaining 4-hydroxyl group, deisopropylidenation of the diol, oxidation of the 35 diol to a dialdehyde, and reduction of the dialdehyde, followed by protection of the 2-hydroxymethyl group

with t-butyldiphenylsilyl and treatment with base (see Figure 5).

Method of Conversion Illustrated in Figure 4

As illustrated in Figure 4, in one method, 1,6-thioanhydro-L-gulose **9** is initially oxidized with NaIO₄ or other oxidizing agent, including KIO₄ or Pb(OAc)₄, at low temperature (usually 0 to -20°C, and typically approximately -10°C), in a suitable solvent such as methanol/water, to cleave the 2,3-cis diol. The resulting dialdehyde is then reduced with NaBH₄ or any borohydride to provide the corresponding vicinal diol. The diol is then protected, preferably with an isopropylidene group, using, for example, CH₃C(OCH₃)₂CH₃ and p-toluenesulfonic acid at room temperature. The reaction can also be performed with acetone and p-toluenesulfonic acid, optionally with cupric sulfate at room temperature. The hydroxymethyl group of the isopropylidene derivative **10** is then protected using methods known to those skilled in the art, typically with t-butyldiphenylsilyl chloride in DMF at room temperature, and then the diol is deprotected to form compound **11**. Other protecting groups known to those skilled in the art can also be used.

Alternatively, compound **9**, 1,6-dideoxy-1,6-thioanhydro-L-gulose can be converted to compound **18** (2R,5S)-5-formyl-2-hydroxymethyl-5-1,3-oxathiolane by: (1) oxidation with NaIO₄ at low temperature (typically dropwise addition of NaIO₄ at -10°C over 20 minutes, with additional stirring for ten minutes) followed by (2) reduction with NaBH₄ or any borohydride under similar conditions as used for **10** to provide the corresponding diol, which, without isolation, is (3) further treated with NaIO₄.

The primary hydroxyl group of the aldehyde **18** is protected with a benzoyl or silyl group to give **19**,

which on treatment with pyridinium dichromate to afford the common intermediate 12, (2R,5S)-2-(protected-oxymethyl)-1,3-oxathiolane-5-carboxylic acid.

5 Method of Conversion Illustrated in Figure 5

In the first step, the cis-hydroxyl groups of 9 are selectively protected, preferably with an isopropylidene group, to provide 2,3-O-(diprotected)-1,6-thioanhydro-L-gulose 20. The isopropylidene
10 derivative can be prepared with dimethoxypropane and p-toluenesulfonic acid. The 2,3-O-(diprotected)-1,6-thioanhydro-L-gulose 20 without isolation is then protected at the 4-position (see Figure 5). A preferred protecting group is benzoyl, however, other
15 protecting groups known to those skilled in the art can also be used. The isopropylidene or other protecting group on the 2 and 3 hydroxyl groups is then removed with catalytic amounts of an acid such as sulfuric acid, hydrochloric acid, formic acid,
20 trifluoroacetic acid, or sulfamic acid in 60% aqueous dioxane or other suitable solvent typically at a temperature range of approximately 0 to 75°C to give 4-O-benzoyl-1,6-thioanhydro-L-gulose 22 in high yield as a solid. The cis diol of 22 is oxidatively
25 cleaved to the dialdehyde 23 using lead tetraacetate in ethyl acetate. The dialdehyde 23 is reduced using sodium borohydride to give 24 which is protected at the 2-hydroxymethyl by a t-butyldiphenylsilyl group to give 25. Treatment of 25 with ammonium hydroxide
30 affords 11.

Compound 12 is used in a modified Hunsdiecker reaction (Dhavale, D.; et al., Tetrahedron Lett., 1988, 29, 6163) with Pb(OAc)₄ to provide the corresponding key chiral intermediates (2R,5R)- and
35 (2R,5S)-5-acetoxy-2-(protected-oxymethyl)-1,3-

oxathiolane (see compounds 13, Figure 4) in good yield.

**B. Condensation of a Heterocyclic Base
with the 1,3-Oxathiolane Derivative**

5 In the next stage of this process for the preparation of enantiomerically pure 1,3-oxathiolane nucleosides, the key chiral intermediates (2R,5R)- and (2R,5S)-5-acetoxy-2-(protected-oxymethyl)-1,3-oxathiolane (see compounds 13, Figure 4) are condensed with a protected heterocyclic base in the presence of trimethylsilyl triflate (trimethylsilyl trifluoromethanesulfonate) or a Lewis acid in a dry organic solvent to provide a mixture of 1'- α and 1'- β nucleosides that can be separated chromatographically or by other methods known to those in the art. The choice of catalyst for condensation may affect the final product ratio of α to β nucleoside product.

Any compound containing a nitrogen that is capable of reaction with a center of electron deficiency can be used in the condensation reaction. Purine bases include adenine, hypoxanthine, guanine, N⁶-alkylpurines, N⁶-benzylpurine, 6-halopurine, 2,6-dihalopurine, N⁶-vinylpurine, N⁶-acetylenic purine, N⁶-acyl purine, 6-hydroxyalkyl purine, and 6-thioalkyl purine. Pyrimidine bases include thymine, cytosine, 5-azapyrimidine, 2-mercaptopyrimidine, uracil, 5-alkylpyrimidines, 5-benzylpyrimidines, 5-halopyrimidines, including 5-fluoropyrimidines such as 5-fluorocytidine, 5-vinylpyrimidine, 5-acetylenic pyrimidine, 5-acyl pyrimidine, 5-hydroxyalkyl pyrimidine, 5-thioalkyl pyrimidine, 6-thiophenyl and 6-selenylphenyl pyrimidines.

Functional oxygen and nitrogen groups on the heterocyclic base should be protected before condensation with the sugar. Protecting groups are

well known to those skilled in the art, and include trimethylsilyl, dimethylhexylsilyl, and t-butyl-diphenylsilyl, tritylmethyl, alkyl groups, acyl groups such as acetyl and propionyl, methylsulfonyl, and p-toluylsulfonyl.

Friedel-Crafts catalysts (Lewis acids) that can be used in the condensation reaction include SnCl_4 , ZnCl_4 , TiCl_4 , AlCl_3 , FeCl_3 , BF_3 -diethylether, and BCl_3 . These catalysts require anhydrous conditions because the presence of water reduces their activity. The catalysts are also inactivated in the presence of organic solvents with active hydrogens, such as alcohols and organic acids. The catalysts are typically used in solvents such as carbon disulfide, methylene chloride, nitromethane, 1,2-dichloroethane, nitrobenzene, tetrachloroethane, chlorobenzene, benzene, toluene, dimethylformamide, tetrahydrofuran, dioxane, or acetonitrile. Anhydrous aluminum chloride is not soluble in carbon disulfide. Niedballa, et al., J. Org. Chem. 39, 25 (1974). The preferred catalyst is SnCl_4 . Useful solvents are 1,2-dichloroethane and methylene chloride.

Trimethylsilyl triflate can be used under the same conditions described above for the Friedel-Crafts catalysts. The reaction proceeds at a temperature range of from -10°C to 200°C .

In the final step of this method of preparation of enantiomerically pure β -L-(-)-1,3-oxathiolane-nucleosides, the 5'-O-position of the nucleoside is deprotected. Desilylation can be carried out with a variety of reagents, including acetic acid, trifluoroacetic acid, hydrogen fluoride, n-tetrabutylammonium fluoride, potassium fluoride and pyridinium HCl . Acetic acid is preferred for commercial scale use because it is inexpensive. Other

reagents for desilylation are known to those skilled in the art. Deacylation is accomplished in acid or base. 5-O-Ethers can be cleaved with BCl_3 or trimethylsilyl iodide.

5 The method of preparation of enantiomerically pure β -L-(-)-1,3-oxathiolane-nucleosides is further illustrated in the following working example for the preparation of β -L-(-)-1-[(2 β ,4 β)-2-(hydroxymethyl)-4-(1,3-oxathiolane)]cytosine (BCH-189). The
10 enumeration of compounds in the working examples refer to structures set out in Figures 3 and 4.

1,2,3,4-Tetra-O-acetyl-6-O-tosyl-L-gulopyranoside 7.

To a suspension of L-gulose 6 (48.7 g, 0.27 mol)
15 in dry pyridine (450 mL) was added dropwise a solution of p-toluenesulfonyl chloride (77.1 g, 0.405 mol, 1.5 eq) in pyridine (300 mL). The internal temperature was maintained between 18-20°C during the addition using an ice bath. On completion of addition the
20 reaction was allowed to rise to room temperature and stirring continued until TLC indicated the absence of starting material (4 h). The reaction mixture was cooled and acetic anhydride (142 mL, 1.29 mol, 4.8 eq) was added dropwise, again maintaining the internal
25 temperature between 18-20°C. On completion of addition the reaction mixture was allowed to come to room temperature and stirred for 4 hr. The reaction mixture was concentrated under reduced pressure and the residue partitioned between ethyl acetate and
30 water. The organic layer was washed with 1% aq H_2SO_4 (2x), H_2O , and sat. aq NaHCO_3 solution (2x), dried (MgSO_4) filtered and concentrated. The residue was dried at high vacuum to give 7 (135.84 g, 96.7%) as a foam which was used in the next step without further
35 purification.

2,3,4-Tri-O-acetyl-1-bromo-6-O-tosyl- α -L-gulopyranoside 8.

To a 1L round bottom flask containing **7** (132 g, 0.25 mol) in acetic acid, cooled in an ice water bath was added HBr in acetic acid (45% w/v, 136 mL, 3 eq.). The flask was fitted with a CaCl₂ tube and stirred in the ice bath for 30 min. and then at room temperature for 15 h. The solvent was removed under reduced pressure and the residue partitioned between ethyl ether and cold water. The organic layer was washed twice with cold water and twice with cold sat. aq NaHCO₃ solution, dried (MgSO₄), filtered and concentrated. The residue was dried at high vacuum to give **8** (136.6 g, 99%) as a hygroscopic foam which was used without further purification.

1,6, Dideoxy-1,6-thioanhydro-L-gulose 9.

To a solution of **8** (136.6 g, 0.261 mol) in acetone (1L) was added potassium O-ethyl xanthate (134 g, 0.835 mol, 3.2 eq.) and the reaction mixture was refluxed for 3 hours at which time TLC indicated complete disappearance of starting material and the thioanhydro triacetate. The reaction mixture was cooled and the solid filtered. The filtrate was concentrated and the residue partitioned between water and chloroform. The chloroform layer was washed with water, sat. sodium bicarbonate solution and brine, dried, filtered and concentrated. The residue was dissolved in methanol and treated with conc. ammonium hydroxide solution (4:1) and allowed to stir overnight. The reaction mixture was concentrated and the residue chromatographed over silica gel using 7% MeOH in chloroform as eluant to give **9** (33.4 g, 72%) as a crystalline solid from isopropanol. NMR (DMSO-d₆) δ 2.8 (dd, J = 6.6 and 10.1 Hz, 1 H, 6a-H), 3.1 (d, J

= 10.1 Hz, 1 H, 6b-H), 3.4-3.8 (complex multip., 3H, 2-H, 3-H, 4-H), 4.5 (d, J = 5 Hz, 1 H OH), 4.55 (dd, J = 5.94 and 6.37 Hz, 1 H, 5-H), 4.82 (d, J = 4.6 Hz, 1 H, OH), 5.1 (d, J = 4.4 Hz, 1 H, OH), 5.35 (d, J = 2.2 Hz, 1 H, 1-H). $[\alpha]_D = -79.2$ (c 1.06, MeOH); Anal. Calcd for $C_6H_{10}O_4S$: C, 40.4; H, 5.66; S, 17.99. Found: C, 40.42; H, 5.67; S, 17.89.

10 (1'S,2R,5R)-2-hydroxymethyl-5-(1',2'-O-isopropylidene)ethyl-1,3-oxathiolane 10.

To a solution of 9 (1.8 g, 10.11 mmol) in MeOH (30 mL), an aqueous solution (30 mL) of $NaIO_4$ (2.99g, 14.15 mmol) was added dropwise at $-10^\circ C$ over 20 min and the mixture was stirred at $-10^\circ C$ for 10 min. $NaBH_4$ was added and the mixture was further stirred at $-10^\circ C$ for 10 min. After filtration, the filtrate was neutralized with glacial acetic acid at $0^\circ C$ and solvents were evaporated. The residue was filtered through a short silica gel pad using $CHCl_3$ -MeOH (10:1) as an eluent to remove inorganic salts. Solvents were evaporated and the residue was treated with acetone (150 mL), 2,2-dimethoxypropane (20 mL) and p -TsOH \cdot H $_2$ O (2.01 g, 10.11 mmol) and stirred at room temperature for 1 hour. The mixture was neutralized with triethylamine, filtered and evaporated. The residue was dissolved in EtOAc (150 mL), washed with H $_2$ O and brine, dried ($MgSO_4$) and evaporated to give a crude residue which was purified by silica gel column chromatography (hexanes : ethyl acetate = 1:1) to yield isopropylidene 10 (1.33 g, 60%) as a colorless syrup.

1H NMR ($CDCl_3$) δ 1.38 and 1.45 (2 x s, 6 H, isopropyl), 2.35 (br s, 1H, OH), 2.83 (dd, J = 10.2 and 3.96 Hz, 1 H, 4-H $_a$), 2.98 (dd, J = 5.49 and 1.76 Hz, 1 H, 4-H $_b$), 3.85 (dd, J = 6.59 and 6.15 Hz, 2 H, CH_2 -OH), 4.04

(ddd, $J = 3.08, 2.42$ and 1.76 Hz, 2 H, 2'-CH₂-O), 4.15 (dd, $J = 4.18$ and 3.73 Hz, 1 H, 5-H), 4.30 (dd, $J = 6.37$ and 6.38 Hz, 1 H, 1'-CH), 5.33 (dd, $J = 3.53$ and 3.53 Hz, 1 H, 2-H).

5

(1'S,2R,5R)-2-(*t*-Butyldiphenylsiloxymethyl)-5-(1'-2'-dihydroxy)ethyl-1,3-oxathiolane 11.

To a solution of 10 (1.5 g, 6.82 mmol) in DMF (20 mL), imidazole (0.928 g, 13.64 mmol) and *tert*-butyldiphenylsilyl chloride (2.66 mL, 10.23 mmol) were added and the mixture was stirred at room temperature for 1 hour. DMF was evaporated and the residue was dissolved in EtOAc (150 mL), washed with H₂O and brine, dried (MgSO₄) and evaporated to give a crude residue, which, without further purification, was treated with 10% HCl in MeOH (20 mL v/v) at 0°C and stirred for 30 min. The mixture was neutralized with NaHCO₃, diluted with EtOAc (200 mL) and separated. The aqueous layer was extracted with EtOAc (150 mL x 2) and the combined organic layers were washed with water and brine, dried (MgSO₄), evaporated to give a residue which was purified by silica gel column chromatography to give protected diol 11 (1.8 g, 63.4%) as a colorless syrup.

¹H NMR(DMSO-d₆) δ 1.00 (s, 9 H, *t*-butyl), 2.82 (d, $J = 7.5$ Hz, 1 H, 4-H_a), 2.98 (dd, $J = 3.75$ and 7.5 Hz, 1 H, 4-H_b), 3.45 (m, 2 H, 2-CH₂-OSi), 3.5-4.4 (m, 4 H, 1'-H, 2'-H and 5-H), 4.58 (t, $J = 5.27$ Hz, 1 H, 2'-CH₂OH), 4.77 (d, $J = 5.49$ Hz, 1 H, 1'-CHOH), 5.22 (t, $J = 5.5$ Hz, 1 H, 2-H), 7.37 - 7.72 (m, 10 H, 2 x C₆H₅).

(2R,5(R,S))-5-Acetoxy-2-(t-butyldiphenylsiloxymethyl)-1,3-oxathiolane 13.

To a solution of 11 (0.9 g, 2.15 mmol) in EtOAc (40 mL), Pb(OAc)₄ (0.95 g, 2.15 mmol) was added and the mixture was stirred at room temperature for 10 minutes under N₂. The mixture was filtered through a celite pad and washed with EtOAc successively. The organic layer was washed with sat. NaHCO₃ (50 mL x 3), H₂O and brine, dried (MgSO₄) and evaporated. The crude aldehyde was dissolved in DMF (20 mL) followed by pyridinium dichromate (2.01 g, 5.38 mmol) and the mixture was stirred at room temperature for 24 hours. The mixture was poured into H₂O (30 mL) and extracted with ether (200 mL x 3). The combined organic layers were washed with H₂O and brine, dried (MgSO₄) and evaporated to give crude acid 12 (0.84 g). Crude acid 12 was dissolved in anhydrous THF (15 mL) followed by Pb(OAc)₄ (1.1 g, 2.58 mmol) and pyridine (0.188 mL, 2.58 mmol) and the mixture was stirred at room temperature for 30 minutes under N₂. The mixture was filtrated through a celite pad and washed with THF successively. After removal of solvent, the residue was purified by silica gel column chromatography (hexanes: ethyl acetate = 5:1) to give acetate 13 (0.59 g, 66% from 11) as a colorless syrup. ¹H NMR (CDCl₃) δ 1.06 and 1.09 (2 x s, 9 H, t-butyl), 1.88 and 2.09 (s, 3 H, OCOCH₃), 3.01 - 3.38 (m, 2 H, 4-H), 3.66 - 4.25 (m, 2 H, CH₂-OSi), 5.38 - 5.53 (m, 1 H, 2-H), 7.31 - 7.77 (m, 10 H, 2 x C₆H₅).

(2R,5(R,S))-10[2-(t-Butyldiphenylsiloxymethyl)-1,3-oxathiolan-5-yl]-N⁴-acetylcytosine 14 and 15.

A stirred suspension of N-acetyl cytosine (6.531 g, 3.47 mmol, 1.5 eq) and (NH₄)₂SO₄ (10 mg, 0.075 mmol)

in hexamethyldisilazane (HMDS, 25 mL) was heated to reflux under argon until a clear solution was obtained (3h). The solution was allowed to cool to room temperature and the HMDS removed under reduced pressure using anhydrous conditions.

To the solid obtained was added 1,2-dichloroethane (dried over CaH and distilled) 40 mL) followed by the acetate 13 (0.965 g, 2.314 mmol) in 1,2-dichloroethane (30 mL). This suspension was cooled in an ice/water bath to 5°C and treated with trimethylsilyltriflate (0.7 mL, 3.47 mmol, 1.5 eq). The reaction mixture became a solution and was allowed to warm to room temperature and stir for 1.5 h at which time the reaction was judged complete by TLC. The reaction mixture was poured in ethyl acetate (300 mL) and 5% NaHCO₃ solution (50 mL) and allowed to be stirred for 20 min. The ethyl acetate layer was separated, washed once with sat. NaHCO₃ solution and twice with H₂O, dried, filtered, and concentrated. The residue was separated by chromatography over silica to obtain three fractions: 14, 0.2 g; 15, 0.25 g, 14 + 15 mix 15 major 0.15 g, total 0.6 g (50%).

14 (α isomer): ¹H NMR: (CDCl₃) δ 1.07 (s, 9 H, t-butyl-Si), 2.28 (s, 3 H, Ac), 3.14 (d, J_{4a,4b} = 12.11 Hz, 1 H, 4a-H), 3.54 (dd, J_{5,4} = 4.1 Hz, J_{4a,4b} = 12.11 Hz, 1 H, 4b-H), 3.74 (d, J_{2,2-CH2-OH} = 4.4 Hz, 2H, 2-CH₂-OH), 5.62 (t, J_{2,2-CH2-OH} = 4.4 Hz, 1 H, 2-H), 6.35 (d, J_{5,4} = 4.1 Hz, 1 H, 5-H), 7.3-7.85 (complex multiplet, 12 H, Ar-Si and H-5, H-6), 9.91 (bs, 1 H, NHAc); UV (MeOH) λ_{max} 297 nm, (H⁺) 311 nm.

15 (β isomer): ¹H NMR: (CDCl₃) δ 1.11 (s, 9 H, t-butyl Si), 2.24 (s, 3 H, Ac), 3.20 (dd, J_{5,4a} = 2.4 Hz, J_{4a,4b} = 12.5 Hz, 1 H, 4a-H), 3.56 (dd, J_{5,4b} = 5.3 Hz,

$J_{4a,4b} = 12.5$ Hz, 1 H, 4b-H), 3.95 (dd, $J_{2,2-CH_2-OR} = 3.5$ Hz, $J_{CH_2,b-OR} = 11.8$ Hz, 1 H, 2-CH₂-OR), 4.2 (dd, $J_{2,2-CHb-OR} = 3.5$ Hz, $J_{2-CH_2,b-OR} = 11.8$ Hz, 1 H, 2-CH_b-OR), 5.28 (t, $J_{2,2-CH_2,b-OR} = 3.5$ Hz, 1 H, 2-H), 6.35 (dd, $J_{5,4a} = 2.4$ Hz, $J_{5,4b} = 5.3$ Hz, 1 H, 5-H), 7.21 (d, $J_{5,6} = 7.4$ Hz, 1 H, H-5), 7.3-7.8 (complex multiplet, 10 H Ar-Si), 8.28 (d, $J_{5,6} = 7.4$ Hz, 1 H, H-6), 8.88 (bs, 1 H, NHAc); UV (MeOH) λ_{max} 297 nm, (H+) 311 nm.

10 (2R,5R)-1-[2-(t-Butyldiphenylsiloxymethyl)-1,3-oxathiolan-5-yl]cytosine 16.

A solution of the α anomer 14 (0.10 g, 0.196 mmol) in MeOH (10 mL) was treated with NH₃/MeOH (sat. solution 0.5 mL) and the reaction mixture stirred at room temperature until disappearance of starting material was complete (3 hr). The reaction mixture was then concentrated and the residue crystallized from hexane/CH₂Cl₂ to give 0.07 g (76%) of 16 as a white crystalline solid. ¹H NMR: (CDCl₃) δ 1.06 (s, 9 H, t-butyl Si), 3.12 (dd, $J_{5,4a} = 1.1$ Hz, $J_{4a,4b} = 12.3$ Hz, 1 H, 4a-H), 3.51 (dd, $J_{5,4b} = 4.8$ Hz, $J_{4a,4b} = 12.3$ Hz, 1 H, 4b-H), 3.73 (d, $J_{2,2-CH_2-OR} = 4.83$ Hz, 2-CH₂-OR), 5.55 (t, $J_{2,2-CH_2-OR} = 4.83$ Hz, 1 H, 2-H), 5.67 (d, $J_{5,6} = 7.4$ Hz, 1 H, H-5), 5.97 (b, 2 H, NH₂), 6.41 (dd, $J_{5,4a} = 1.1$ Hz, $J_{5,4b} = 4.8$ Hz, 1 H, 5-H), 7.3-7.8 (complex multiplet, 11 H, Ar-Si and H-6); UV (MeOH) λ_{max} 271 nm, (H+) 283 nm.

30 (2R,5S)-1-[2-(Butyldiphenylsiloxymethyl)-1,3-oxathiolan-5-yl]cytosine 17.

A solution of the β anomer 15 (0.15 g, 0.294 mmol) in MeOH (10 mL) was treated with NH₃/MeOH (sat. solution 0.5 mL) and the reaction mixture was allowed to stir at room temperature until the disappearance of starting material was observed (3 h). The reaction

mixture was concentrated under reduced pressure and the residue purified by preparative TLC using 5% MeOH/CHCl₃/0.5NH₄OH as eluant. The material obtained from the plate gave 13 as a solid on trituration with
 5 Hexane and Et₂O, 0.10 g (73%).

¹H NMR: (CDCl₃) δ 1.09 (s, 9 H, t-butyl-Si), 3.13 (dd, J_{5,4a} = 3.3 Hz, J_{4a,4b} = 12.3 Hz, 1 H, 4a-H), 3.5 (dd, J_{5,4a} = 5.27 Hz, J_{4a,4b} = 12.3 Hz, 1 H, 4b-H), 3.92 (dd, J_{2,2-CHa-OR} = 3.74 Hz, J_{2-CHa,b-OR} = 12.8 Hz, 1 H, 2-CHa-OR), 4.16 (dd, J_{2,2-CHb-OR} = 3.5 Hz, J_{2-CHa,b-OR} = 12.8 Hz, 1 H, 2-CHb-OR), 5.25 (app t, J_{2,2-CHa-OR} = 4.16 Hz, J_{2,2-CHb-OR} = 3.5 Hz, 1 H, 2-H), 5.46 (d, J_{5,6} = 7.4 Hz, 1 H, H-5), 5.92 (b, 2 H, NH₂), 6.35 (dd, J_{5,4a} = 3.3 Hz, J_{5,4b} = 5.27 Hz, 1 H, 5-H), 7.3-7.8 (complex multiplet, 10 H, ArSi), 7.94 (d, J_{5,6} = 7.4 Hz, 1 H, H-6); UV (MeOH) λ_{max} 271.5 nm, (H+) 283.5.

(2R,5R)-1-[2-Hydroxymethyl]-1,3-oxathiolan-5-yl]-cytosine 5.

20 To a solution of the α anomer 16 (0.10 g, 0.213 mmol) in THF (20 mL) was added tetrabutylammonium fluoride, 1M in THF (0.24 mL, 0.24 mmol, 1.1 eq) and the reaction mixture was allowed to stir at room temperature until TLC indicated disappearance of
 25 starting material (30 min). The reaction mixture was concentrated under reduced pressure and the residue purified by preparative TLC using 12% MeOH/CHCl₃ as development solvent to give 0.036 g (76%) of 5 as a hygroscopic solid. [α]_D²³ = 146.6 (c 0.55, MeOH) (for
 30 SS isomer 4 [α]_D²³ = -143.18 (c 0.62, MeOH)); ¹H NMR: ((CD₃)₂SO) δ 3.08 (dd, J_{5,4a} = 2.64 Hz, J_{4a,4b} = 12.08 Hz, 1 H, 4a-H), 3.46 (dd, J_{5,4b} = 5.05 Hz, J_{4a,4b} = 12.08 Hz, 1 H, 4b-H), 3.54 (app t on D₂O exchange goes to d, J_{2,2OCH₂-OH} = 5.05 Hz, 2 H, 2-CH₂-OH), 5.16 (t, J_{2-CH₂-OH} = 5.7
 35 Hz, 1 H, 2-CH₂-OH), 5.53 (t, J_{2,2CH₂-OH} = 5.05 Hz, 1 H, 2-

H), 5.83 (d, $J_{5,6} = 7.47$ Hz, 1 H, H-5), 6.36 (dd, $J_{5,4a} = 2.64$ Hz, $J_{5,4b} = 5.05$ Hz, 1 H, 5-H), 7.16 (bs, 2 H, NH_2), 7.63 (d, $J_{5,6} = 7.47$ Hz, 1 H, H-6).

5 (2R,5S)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine 3.

To a solution of the β anomer 17 (0.15 g, 0.32 mmol) in THF (25 mL) was added tetrabutylammonium fluoride 1M in THF (0.35 mL, 0.35 mmol, 1.1 eq) and
 10 the reaction was allowed to stir at room temperature until TLC indicated the disappearance of starting material (30 min). The reaction mixture was concentrated under reduced pressure and the residue purified by preparative TLC using 12% MeOH/ CHCl_3 as
 15 development solvent to give 0.055 g (75%) of 3 from ethyl ether/MeOH (trace) as a white crystalline solid. $[\alpha]_D^{25} = -121.6$ (c 1.1, MeOH) (for the S,R isomer 2 $[\alpha]_D^{25} = 120.96$ (c 1.06, MeOH)); ^1H NMR: ($(\text{CD}_3)_2\text{SO}$) δ 3.03 (dd, $J_{5,4a} = 4.4$ Hz, $J_{4a,4b} = 11.86$ Hz, 1 H, 4a-H),
 20 3.43 (dd, $J_{5,4b} = 5.3$ Hz, $J_{4a,4b} = 11.86$ Hz, 1 H, 4b-H), 3.80 (app t on D_2O exchange goes to d, $J_{2,2-\text{CH}_2-\text{OH}} = 4.17$ Hz, 2 H, 2- CH_2-OH), 5.27 (t, $J_{2-\text{CH}_2-\text{OH}} = 4.6$ Hz, 1 H, 2- CH_2OH), 5.22 (t, $J_{2,2-\text{CH}_2-\text{OH}} = 4.17$ Hz, 1 H, 2-H), 5.88 (d, $J_{5,6} = 7.47$ Hz, 1 H, H-5), 6.21 (app t, $J = 5.05$ and
 25 4.84 Hz, 1 H, 5-H), 7.19 (bs, 2 H, NH_2), 7.89 (d, $J_{5,6} = 7.47$ Hz, 1 H, H-6).

(1'S,2R)-5-formyl-2-hydroxymethyl-5-1,3-oxathiolane 18.

30 To a solution of 9 (1.8 g, 10.11 mmol) in MeOH (30 mL), an aqueous solution (30 mL) of NaIO_4 (2.99 g, 14.15 mmol) was added dropwise at -10°C over 20 min and the mixture was stirred at -10°C for 10 min. NaBH_4 was added and the mixture was further stirred at -
 35 10°C for 10 min. After filtration, the filtrate was

neutralized with glacial acetic acid at -10°C and an aqueous solution (2.99 g, 14.15 mmol) was added dropwise at -10°C over 20 min and the mixture was stirred at -10°C for 10 min. Solvents were evaporated and the residue was dissolved in EtOAc (150 mL), washed with H_2O and brine, dried (MgSO_4) and evaporated to give a crude residue 18 (1.5 g) as a colorless syrup.

10 (1'S,2R)-2-(*t*-Butyldiphenylsiloxymethyl)-5-formyl-1,3-oxathiolane 19.

To a solution of 18 (1.5 g, 10.13 mmol) in DMF (20 mL), imidazole (1.38 g, 20.26 mmol) and *tert*-butyldiphenylsilyl chloride (5.27 mL, 20.26 mmol) were added and the mixture was stirred at room temperature for 1 hour. DMF was evaporated and the residue was dissolved in EtOAc (150 mL), washed with H_2O and brine, dried (MgSO_4) and evaporated to give a crude aldehyde 19 (3.9 g).

(2R,5(R,S))-5-Acetoxy-2-(*t*-butyldiphenylsiloxymethyl)-1,3-oxathiolane 13.

The crude aldehyde 19 (3.9 g, 10.10 mmol) was dissolved in DMF (40 mL) followed by pyridinium dichromate (9.50 g, 25.25 mmol) and the mixture was stirred at room temperature for 24 hours. The mixture was poured into H_2O (50 mL) and extracted with ether (300 mL x 3). The combined organic layers were washed with H_2O and brine, dried (MgSO_4) and evaporated to give crude acid 12 (3.0 g). Crude acid 7 (3.0 g, 7.46 mmol) was dissolved in anhydrous THF (15 mL) followed by $\text{Pb}(\text{OAc})_4$ (3.17 g, 7.46 mmol) and pyridine (0.55 mL, 7.46 mmol) and the mixture was stirred at room temperature for 30 minutes under N_2 . The mixture was filtrated through a celite pad and washed with THF

successively. After removal of solvent, the residue was purified by silica gel column chromatography (hexanes: ethyl acetate = 5:1) to give acetate 13 (2.17 g, 52% from 4) as a colorless syrup.

5 ¹H NMR (CDCl₃) δ 1.06 and 1.09 (2 x s, 9 H, t-butyl), 1.88 and 2.09 (s, 3 H, OCOCH₃), 3.01 - 3.38 (m, 2 H, 4-H), 3.66 - 4.25 (m, 2 H, CH₂-OSi), 5.38 - 5.53 (m, 1 H, 2-H), 7.31 - 7.77 (m, 10 H, 2 x C₆H₅).

This invention has been described with reference
10 to its preferred embodiments. Variations and modifications of the invention, enantiomerically pure β-L-(-)-1,3-oxathiolane-nucleosides, will be obvious to those skilled in the art from the foregoing detailed description of the invention. It is intended
15 that all of these variations and modifications be included within the scope of the appended claims.

We claim:


1. A process for the preparation of enantiomerically pure β -L-(-)-1,3-oxathiolane nucleosides comprising preparing the 1,3-oxathiolane ring from 1,6-dideoxy-1,6-thioanhydro-L-gulose.
2. The process of claim 1 further comprising converting 1,6-dideoxy-1,6-thioanhydro-L-gulose to 2R,5(R,S)-5-(O-protected)-2-(protected-oxymethyl)-1,3-oxathiolane.
3. The process of claim 2 further comprising condensing the (2R,5R) - and (2R,5S)-5-(O-protected)-2-(protected-oxymethyl)-1,3-oxathiolane with a heterocyclic base selected from the group consisting of a purine base and a pyrimidine base.
4. The process of claim 1 further comprising the steps of preparing 1,6-thioanhydro-L-gulose from L-gulose.
5. The process of claim 4, further comprising:
 - i) protecting the hydroxyl groups on L-gulose to form a 1,2,3,4-tetra-O-(protected)-6-O-(protected)-L-gulopyranoside;
 - ii) converting the 1,2,3,4-tetra-O-(protected)-6-O-(protected)-L-gulopyranoside to 2,3,4-tri-O-(protected)-1-halo-6-O-(protected)- α -L-gulopyranoside;
 - iii) reacting 2,3,4-tri-O-(protected)-1-halo-6-O-(protected)- α -L-gulopyranoside with a compound selected from the group consisting of potassium O-ethyl xanthate, NaSH, and $(\text{Na})_2\text{S}$, to form 2,3,4-tri-O-(protected)-1,6-dideoxy-1,6-thioanhydro-L-gulose; and
 - iv) deprotecting 2,3,4-tri-O-(protected)-1,6-dideoxy-1,6-thioanhydro-L-gulose to produce 1,6-thioanhydro-L-gulose.

6. The process of claim 2 further comprising:
- i) protecting the 2, 3, and 4-hydroxyl groups of 1,6-thioanhydro-L-gulose to produce 2,3,4-O-(triprotected)-1,6-dideoxy-1,6-thioanhydro-L-gulose;
 - ii) deprotecting the 2 and 3 positions of 2,3,4-O-(triprotected)-1,6-dideoxy-1,6-thioanhydro-L-gulose to form a 4-O-protected-1,6-dideoxy-1,6-thioanhydro-L-gulose;
 - iii) oxidatively cleaving the glycol of 4-O-protected-1,6-dideoxy-1,6-thioanhydro-L-gulose to the corresponding dialdehyde; and
 - iv) oxidizing the dialdehyde to (2R,5(R,S))-2-(protected-oxymethyl)-1,3-oxathiolane-5-carboxylic acid.
7. The process of claim 6, wherein the (2R,5(R,S))-2-(protected-oxymethyl)-1,3-oxathiolane-5-carboxylic acid is reacted with Pb(O-acetate)₄ to produce (2R,5R)- and (2R,5S)-5-acetoxy-2-(protected-oxymethyl)-1,3-oxathiolane.
8. The process of claim 3, wherein the heterocyclic base is selected from the group consisting of adenine, hypoxanthine, guanine, N⁶-alkylpurines, N⁶-benzylpurine, N⁶-halopurine, N⁶-vinylpurine, N⁶-acetylenic purine, N⁶-acyl purine, N⁶-hydroxyalkyl purine, 2,6-dihalopurine, N⁶-thioalkyl purine, thymine, cytosine, 6-azapyrimidine, 2-mercaptopyrimidine, uracil, 5-alkylpyrimidines, 5-benzylpyrimidines, 5-halopyrimidines, 5-vinylpyrimidine, 5-acetylenic pyrimidine, 5-acyl pyrimidine, 5-hydroxyalkyl pyrimidine, 5-azapyrimidine, 5-thioalkyl pyrimidine, 6-thiophenyl pyrimidine, and 6-selenophenyl pyrimidine.
9. The process of claim 8, wherein the heterocyclic base is thymine.

10. The process of claim 1, wherein the 1,3-oxathiolane nucleoside is β -L-(-)-1-[(2B,4B)-2-(hydroxymethyl)-4-(1,3-thioxolane)]cytosine.
11. The compound 1,6-thioanhydro-L-gulose.
12. A process for the preparation of a 1,3-oxathiolane comprising the step of oxidizing 1,6-thioanhydro-L-gulose or a protected derivative thereof to 2-formyl-5-(2'-(2'-hydroxyacetaldehyde)-1,3-oxathiolane, or a protected derivative thereof.
13. The process of claim 12, further comprising reducing 2-formyl-5-(2'-(2'-hydroxyacetaldehyde)-1,3-oxathiolane to 2-hydroxymethyl-5-(2'-(1',2'-dihydroxyethyl)-1,3-oxathiolane.
14. The process of claim 13, further comprising:
 - (i) protecting the cis diol of 2-hydroxymethyl-5-(2'-(1',2'-dihydroxyethyl)-1,3-oxathiolane;
 - (ii) protecting the 2-hydroxymethyl group;
 - (v) deprotecting the 2,3-cis diol; and
 - (vi) oxidizing the diol to form (2R,5S)-2-(protected-oxymethyl)-1,3-oxathiolane-5-carboxylic acid.

THIS PAGE BLANK (USPTO)

1/4



1, 3 - Oxathiolane Nucleoside

wherein:

B = heterocyclic base


X = C4' chiral carbon atom

Y = C1' chiral carbon atom


FIGURE 1

THIS PAGE BLANK (USPTO)


2/4 Figure 2




(±)-BCH189
β-DL-(±)




β-D-(+)



β-L-(-)



α-D-(-)




α-L-(+)

THIS PAGE BLANK (USPTO)

3/4

Figure 3



THIS PAGE OF LXX (CSP)

U.S. SPACE ADMINISTRATION

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/09123

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) *

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC (5): C07D 475/00, 487/00, 239/02, 405/04, 473/00

U.S.C.I.: 544/261, 262, 266, 277, 310, 313, 314, 317; 549/214, 358, 397, 449, 453

II. FIELDS SEARCHED

Classification System

Minimum Documentation Searched

U.S.

Classification Symbols
544/261, 262, 266, 277, 310, 313, 314, 317
549/214, 358, 397, 449, 453

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched *

CAS ONLINE

III. DOCUMENTS CONSIDERED TO BE RELEVANT *

Category *	Citation of Document, ** with indication, where appropriate, of the relevant passages **	Relevant to Claim No. **
A P	US, A, 5,041,449 (IAF BIOCHEM INTERNATIONAL, INC.) 20 August 1991; See the entire document and Flowsheet I and II.	1-14
A	EP - 382,526 (IAF BIOCHEM INTERNATIONAL, INC.) 16 August 1990. See the entire document.	1-14
A	Daniel W. Norbeck et al., Tetrahedron Letters, Vol. 30, No. 46, pp. 6263-6266, 1989. "A New 2', 3' - dideoxynucleoside Prototype with in vitro activity against HIV", see the entire document.	1-14
A	Phillip A. Furman et al. Proc. Natl. Acad. Science, U.S.A. Vol. 83, pp. 8333-8337, 1986 "Phosphorylation of 3' - azido - 3' - deoxy - thymidine and selective interaction of the 5' - triphosphate with human immunodeficiency virus reverse transcriptase" see the entire document.	1-14

* Special categories of cited documents: **

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Δ" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

Date of Mailing of this International Search Report

07 March 1992

16 APR 1992

International Searching Authority

Signature of Authorized Officer

ISA/US

Cecilia Tsang

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

- | | | |
|---|--|------|
| A | Martin et al., J. Med. Chem. 1990, 33, 2137-2145. "Synthesis and antiviral activity of Monofluoro and difluoro analogues of pyrimidine deoxyribonucleosides against human Immunodeficiency virus (HIV-1). see the entire document. | 1-14 |
| A | Jan Balzarini et al., Biochem and Biophys. Res. Comm. Vol. 140, no. 2, 1986 pp. 735-742. "Potent and Selective anti-HTLV-III/LAV Activity of 2', 3' - dideoxy - cytidivene, the 2', 3' - unsaturated derivative of 2', 3' - dideoxycytidine." See the entire document. | 1-14 |

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers _____ because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim numbers _____ because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out 13, specifically:
3. ☐ Claim numbers _____ because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, ¹ with indication, where appropriate, of the relevant passages ²	Relevant to Claim No. ³
------------	--	------------------------------------

- | | | |
|---|--|------|
| A | Chung K. Chu et al., J. Med. Chem. 1989, Vol. 32, No. 3, pp. 612-617. "Structure - activity relationships of pyrimidine nucleosides as antiviral agents for human immunodeficiency virus type 1 in peripheral blood mononuclear cells." See the entire document. | 1-14 |
| A | Patrick Van Roey et al. J.A.C.S. 1988, Vol. 110, pp. 2277-2282. "Solid - State Conformation of anti-human immunodeficiency virus type - 1 agents: crystal structures of three 3' -azido- 3' deoxythymidine Analogues". See the entire document. | 1-14 |

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)